Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases

Estimates of the contribution of BRCA1 and BRCA2 to breast cancer incidence in outbred populations have been based on studies that are either small or have selected for cases diagnosed at an early age. Only one of these has reported an estimate of the breast cancer risk associated with a mutation in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer 2000-11, Vol.83 (10), p.1301-1308
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1308
container_issue 10
container_start_page 1301
container_title British journal of cancer
container_volume 83
description Estimates of the contribution of BRCA1 and BRCA2 to breast cancer incidence in outbred populations have been based on studies that are either small or have selected for cases diagnosed at an early age. Only one of these has reported an estimate of the breast cancer risk associated with a mutation in these genes, and there is no published ovarian cancer risk estimate derived from a population-based case series. We screened a population-based series of breast cancer cases diagnosed before the age of 55 for mutations in BRCA1 and BRCA2 . Pedigree information from the mutation carriers was used to estimate penetrance and the proportion of familial risk of breast cancer due to BRCA1 and BRCA2 . We identified eight (0.7%) BRCA1 and 16 (1.3%) BRCA2 mutation carriers in 1220 breast cancer cases (actual sample size 1435 adjusted for 15% polymerase chain reaction failure rate). Mutation prevalence was substantially higher in cases diagnosed before 35 years-of-age and with increasing number of relatives affected with breast or ovarian cancer. However, most mutation carriers were diagnosed in the older age groups, and a minority reported a first-degree relative with breast cancer. Breast cancer penetrance by age 80 was estimated to be 48% (95% CI 7–82%) for BRCA1 mutation carriers and 74% (7–94%) for BRCA2 mutation carriers. Ovarian cancer penetrance for BRCA1 and BRCA2 combined was 22% (6–65%) by age 80. 17% of the familial risk of breast cancer was attributable to BRCA1 and BRCA2 . At birth, the estimated prevalence of BRCA1 mutation carriers was 0.07% or 0.09% depending on the penetrance function used for the calculation. For BRCA2 the birth prevalence estimates were 0.14% and 0.22%. Mutations in the genes BRCA1 and BRCA2 are rare in the population and account for a small fraction of all breast cancer in the UK. They account for less than one fifth of the familial risk of breast cancer. Eligibility criteria for BRCA1 and BRCA2 mutation testing based on family history and age of onset will identify only a small proportion of mutation carriers. © 2000 Cancer Research Campaign
doi_str_mv 10.1054/bjoc.2000.1407
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2408797</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17733492</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-ade18c5e7d4dbfc7aea0ba36d16a5b49557e7cd3f26488dd37f659cbf66708353</originalsourceid><addsrcrecordid>eNp1UcFq3DAQFaWh2aS99iwo9OaNZEmWfSmkS9sUAgmlPQtZGqdevJKrsQP5-0rZJdBDT6N58-YNeo-Q95xtOVPyqt9Ht60Zy61k-hXZcCXqire1fk02GdYV62p2Ti4Q97ntWKvfkHPOmZRCyQ3Z3yd4tBMEB9QGT2cIsCRb2jjQzz921_wZL6-aHtbFLmMMSMdALZ3jvE7PQNVbBE8R0ghYNvsEFhfqilLKBQHfkrPBTgjvTvWS_Pr65efuprq9-_Z9d31bOdnppbIeeOsUaC99PzhtwbLeisbzxqpedkpp0M6LoW5k23ov9NCozvVD02jWCiUuyaej7rz2B_AOQv7QZOY0Hmx6MtGO5t9JGH-bh_hoapnd6XQW-HgSSPHPCriYw4gOpskGiCsarrUQsqszcXskuhQREwwvRzgzJR5T4jElHlPiyQsfTsoWnZ2GYvSIL1u61bqRmXV1ZGEehAdIZh_XFLJn_9P9CzTfn3A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17733492</pqid></control><display><type>article</type><title>Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases</title><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><description>Estimates of the contribution of BRCA1 and BRCA2 to breast cancer incidence in outbred populations have been based on studies that are either small or have selected for cases diagnosed at an early age. Only one of these has reported an estimate of the breast cancer risk associated with a mutation in these genes, and there is no published ovarian cancer risk estimate derived from a population-based case series. We screened a population-based series of breast cancer cases diagnosed before the age of 55 for mutations in BRCA1 and BRCA2 . Pedigree information from the mutation carriers was used to estimate penetrance and the proportion of familial risk of breast cancer due to BRCA1 and BRCA2 . We identified eight (0.7%) BRCA1 and 16 (1.3%) BRCA2 mutation carriers in 1220 breast cancer cases (actual sample size 1435 adjusted for 15% polymerase chain reaction failure rate). Mutation prevalence was substantially higher in cases diagnosed before 35 years-of-age and with increasing number of relatives affected with breast or ovarian cancer. However, most mutation carriers were diagnosed in the older age groups, and a minority reported a first-degree relative with breast cancer. Breast cancer penetrance by age 80 was estimated to be 48% (95% CI 7–82%) for BRCA1 mutation carriers and 74% (7–94%) for BRCA2 mutation carriers. Ovarian cancer penetrance for BRCA1 and BRCA2 combined was 22% (6–65%) by age 80. 17% of the familial risk of breast cancer was attributable to BRCA1 and BRCA2 . At birth, the estimated prevalence of BRCA1 mutation carriers was 0.07% or 0.09% depending on the penetrance function used for the calculation. For BRCA2 the birth prevalence estimates were 0.14% and 0.22%. Mutations in the genes BRCA1 and BRCA2 are rare in the population and account for a small fraction of all breast cancer in the UK. They account for less than one fifth of the familial risk of breast cancer. Eligibility criteria for BRCA1 and BRCA2 mutation testing based on family history and age of onset will identify only a small proportion of mutation carriers. © 2000 Cancer Research Campaign</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1054/bjoc.2000.1407</identifier><identifier>PMID: 11044354</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; BRCA2 gene ; Cancer Research ; Drug Resistance ; Epidemiology ; Gynecology. Andrology. Obstetrics ; Mammary gland diseases ; Medical sciences ; Molecular Medicine ; Oncology ; Regular ; regular-article ; Tumors</subject><ispartof>British journal of cancer, 2000-11, Vol.83 (10), p.1301-1308</ispartof><rights>The Author(s) 2000</rights><rights>2001 INIST-CNRS</rights><rights>Copyright © 2000 Cancer Research Campaign 2000 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-ade18c5e7d4dbfc7aea0ba36d16a5b49557e7cd3f26488dd37f659cbf66708353</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408797/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408797/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=787764$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><title>Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>Estimates of the contribution of BRCA1 and BRCA2 to breast cancer incidence in outbred populations have been based on studies that are either small or have selected for cases diagnosed at an early age. Only one of these has reported an estimate of the breast cancer risk associated with a mutation in these genes, and there is no published ovarian cancer risk estimate derived from a population-based case series. We screened a population-based series of breast cancer cases diagnosed before the age of 55 for mutations in BRCA1 and BRCA2 . Pedigree information from the mutation carriers was used to estimate penetrance and the proportion of familial risk of breast cancer due to BRCA1 and BRCA2 . We identified eight (0.7%) BRCA1 and 16 (1.3%) BRCA2 mutation carriers in 1220 breast cancer cases (actual sample size 1435 adjusted for 15% polymerase chain reaction failure rate). Mutation prevalence was substantially higher in cases diagnosed before 35 years-of-age and with increasing number of relatives affected with breast or ovarian cancer. However, most mutation carriers were diagnosed in the older age groups, and a minority reported a first-degree relative with breast cancer. Breast cancer penetrance by age 80 was estimated to be 48% (95% CI 7–82%) for BRCA1 mutation carriers and 74% (7–94%) for BRCA2 mutation carriers. Ovarian cancer penetrance for BRCA1 and BRCA2 combined was 22% (6–65%) by age 80. 17% of the familial risk of breast cancer was attributable to BRCA1 and BRCA2 . At birth, the estimated prevalence of BRCA1 mutation carriers was 0.07% or 0.09% depending on the penetrance function used for the calculation. For BRCA2 the birth prevalence estimates were 0.14% and 0.22%. Mutations in the genes BRCA1 and BRCA2 are rare in the population and account for a small fraction of all breast cancer in the UK. They account for less than one fifth of the familial risk of breast cancer. Eligibility criteria for BRCA1 and BRCA2 mutation testing based on family history and age of onset will identify only a small proportion of mutation carriers. © 2000 Cancer Research Campaign</description><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>BRCA2 gene</subject><subject>Cancer Research</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Regular</subject><subject>regular-article</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp1UcFq3DAQFaWh2aS99iwo9OaNZEmWfSmkS9sUAgmlPQtZGqdevJKrsQP5-0rZJdBDT6N58-YNeo-Q95xtOVPyqt9Ht60Zy61k-hXZcCXqire1fk02GdYV62p2Ti4Q97ntWKvfkHPOmZRCyQ3Z3yd4tBMEB9QGT2cIsCRb2jjQzz921_wZL6-aHtbFLmMMSMdALZ3jvE7PQNVbBE8R0ghYNvsEFhfqilLKBQHfkrPBTgjvTvWS_Pr65efuprq9-_Z9d31bOdnppbIeeOsUaC99PzhtwbLeisbzxqpedkpp0M6LoW5k23ov9NCozvVD02jWCiUuyaej7rz2B_AOQv7QZOY0Hmx6MtGO5t9JGH-bh_hoapnd6XQW-HgSSPHPCriYw4gOpskGiCsarrUQsqszcXskuhQREwwvRzgzJR5T4jElHlPiyQsfTsoWnZ2GYvSIL1u61bqRmXV1ZGEehAdIZh_XFLJn_9P9CzTfn3A</recordid><startdate>20001101</startdate><enddate>20001101</enddate><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20001101</creationdate><title>Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-ade18c5e7d4dbfc7aea0ba36d16a5b49557e7cd3f26488dd37f659cbf66708353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>BRCA2 gene</topic><topic>Cancer Research</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Regular</topic><topic>regular-article</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><date>2000-11-01</date><risdate>2000</risdate><volume>83</volume><issue>10</issue><spage>1301</spage><epage>1308</epage><pages>1301-1308</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Estimates of the contribution of BRCA1 and BRCA2 to breast cancer incidence in outbred populations have been based on studies that are either small or have selected for cases diagnosed at an early age. Only one of these has reported an estimate of the breast cancer risk associated with a mutation in these genes, and there is no published ovarian cancer risk estimate derived from a population-based case series. We screened a population-based series of breast cancer cases diagnosed before the age of 55 for mutations in BRCA1 and BRCA2 . Pedigree information from the mutation carriers was used to estimate penetrance and the proportion of familial risk of breast cancer due to BRCA1 and BRCA2 . We identified eight (0.7%) BRCA1 and 16 (1.3%) BRCA2 mutation carriers in 1220 breast cancer cases (actual sample size 1435 adjusted for 15% polymerase chain reaction failure rate). Mutation prevalence was substantially higher in cases diagnosed before 35 years-of-age and with increasing number of relatives affected with breast or ovarian cancer. However, most mutation carriers were diagnosed in the older age groups, and a minority reported a first-degree relative with breast cancer. Breast cancer penetrance by age 80 was estimated to be 48% (95% CI 7–82%) for BRCA1 mutation carriers and 74% (7–94%) for BRCA2 mutation carriers. Ovarian cancer penetrance for BRCA1 and BRCA2 combined was 22% (6–65%) by age 80. 17% of the familial risk of breast cancer was attributable to BRCA1 and BRCA2 . At birth, the estimated prevalence of BRCA1 mutation carriers was 0.07% or 0.09% depending on the penetrance function used for the calculation. For BRCA2 the birth prevalence estimates were 0.14% and 0.22%. Mutations in the genes BRCA1 and BRCA2 are rare in the population and account for a small fraction of all breast cancer in the UK. They account for less than one fifth of the familial risk of breast cancer. Eligibility criteria for BRCA1 and BRCA2 mutation testing based on family history and age of onset will identify only a small proportion of mutation carriers. © 2000 Cancer Research Campaign</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>11044354</pmid><doi>10.1054/bjoc.2000.1407</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 2000-11, Vol.83 (10), p.1301-1308
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2408797
source Nature; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
BRCA2 gene
Cancer Research
Drug Resistance
Epidemiology
Gynecology. Andrology. Obstetrics
Mammary gland diseases
Medical sciences
Molecular Medicine
Oncology
Regular
regular-article
Tumors
title Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T15%3A59%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20and%20penetrance%20of%20BRCA1%20and%20BRCA2%20mutations%20in%20a%20population-based%20series%20of%20breast%20cancer%20cases&rft.jtitle=British%20journal%20of%20cancer&rft.date=2000-11-01&rft.volume=83&rft.issue=10&rft.spage=1301&rft.epage=1308&rft.pages=1301-1308&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1054/bjoc.2000.1407&rft_dat=%3Cproquest_pubme%3E17733492%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17733492&rft_id=info:pmid/11044354&rfr_iscdi=true